• Glimepiride was titrated (1 - 8 mg/day) to a fasting blood sugar goal of 90 - 150 mg/dl
  • Baseline A1C ∼ 9.2% in both groups
  • Reference [2]
Glimepiride (Glim) monotherapy in treatment-naïve diabetics,
placebo-controlled, 22-week trial
Placebo
(N=126)
Glim (1 - 8 mg/day)
(N=123)
HgA1C (%)
(average change
from baseline at 22 weeks)
-1.1% -2.2%

  • Baseline weight ∼ 191 pounds in both groups
  • Reference [2]
Glimepiride (Glim) monotherapy in treatment-naïve diabetics,
placebo-controlled, 22-week trial
Placebo
(N=122)
Glim (1 - 8 mg/day)
(N=119)
Body weight
(average change
from baseline at 22 weeks)
-2 pounds +4 pounds